IBS-C Patients Reduced Medical Visits After Tenapanor
Adults with irritable bowel syndrome with constipation saw fewer clinical visits following the start of tenapanor therapy.
Updated on Oct. 14, 2026 in Nutrition
Live Poll
Is now a good time to consider switching to a new medication for your chronic condition?
A new analysis of 470 patients found that median gastrointestinal healthcare visits dropped from 4.5 to 3.0 in the year after starting tenapanor. This retrospective look at electronic health records suggests a decrease in clinical resource needs for those managing the condition.
Why it matters
The findings help clarify the real-world utility of tenapanor in managing IBS-C, particularly for patients who have already cycled through other medications. As the drug is a relatively new market entrant, understanding its impact on healthcare utilization helps patients and providers assess treatment value.
In a retrospective analysis of 470 patients from national gastroenterology practices, median GI healthcare visits declined from 4.5 to 3.0 in the year following tenapanor initiation. The interquartile range of visits also narrowed, indicating a consistent reduction in resource use.
The players
American College of Gastroenterology
A professional medical society that promotes clinical research and education in the field of digestive health.
Massachusetts General Hospital
A major teaching hospital that conducts clinical and basic research on digestive system disorders.
The details
Tenapanor works by inhibiting the sodium/hydrogen exchanger 3 in the small intestine and colon, which limits the absorption of dietary sodium. This process increases the amount of sodium in the intestinal lumen, which subsequently retains water to soften stool and alleviate constipation symptoms. The study observed these clinical benefits across varying body mass indexes and comorbidity levels.
Timeline
October 12, 2026: Findings were presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.
Health Landscape
This research adds to the growing body of data presented at the American College of Gastroenterology 2026 Annual Scientific Meeting regarding the management of chronic bowel disorders. It reflects a broader shift toward evaluating how newer targeted therapies for IBS-C influence long-term healthcare utilization.
If you are managing IBS-C and have not found relief with other medications, this data suggests that tenapanor may be a consideration for reducing the frequency of your clinic visits. Discuss these findings with your doctor to determine if this therapy is appropriate for your specific health history.
The takeaway
The data highlights a potential link between tenapanor use and reduced gastrointestinal care needs for patients with IBS-C. If you have questions about your current symptom management plan, schedule a follow-up with your gastroenterologist to review your treatment options.
Further reading
For more information on the latest research and clinical developments in gut health, visit our Nutrition section.
Source note: This article includes information reported by Hcplive.
Live Poll
Is now a good time to consider switching to a new medication for your chronic condition?
